SNP Microarrays in MDS/AML: Our Experience
Dr. Laila Mnayer
Thursday, July 28, 2016
Tweet
Transcript
Embed
Email
Bookmark
<<
<
>
>>
Tweet
Facebook
Email
Chapters
Introduction
Myelodysplastic Syndromes
Advantages of Microarrays over Karyotype and FISH in MDS/AML
MDS/AML: Sample Type
Cytoscan HD/SNP Microarray Utilization at Hartford Hospital
Loss of Heterozygosity (LOH) in Cancer
69 year-old male, Persistent Anemia
Patient : 69 year old Male with Persistent Anemia
72 Year-Old Male With MDS , Previously Normal Karyotype: ? Progression
Deletion 5q
58 Year-Old Male/Anemia, Thrombocytopenia and Equivocal Morphology
More than 50 deleted Genes
83 Year-old Male History of MDS
Myelodysplastic Syndrome 83 years old Male
62 Year-Old Female with AML
80 Year-Old Male with AML Disease Progression pt.1
80 Year-Old Male with AML Disease Progression pt.2
66 Year Old Male AML- New Diagnosis pt. 1
66 Year Old Male AML- New Diagnosis pt. 2
4 copies centromere 3
No transcript for this webinar
More Information
Request info
The views and opinions expressed by the guest speakers are solely their own and do not necessarily represent the views or opinions of Affymetrix, Inc.
Any Affymetrix product(s) referenced in this presentation are
For Research Use Only. Not for use in diagnostic procedures.
Please see
affymetrix.com/trademarks
for a complete list of Affymetrix trademarks. All other trademarks are the property of their respective owners.